Pfizer contracts with Antares to build a rescue auto-injector for an unnamed drug

08 August 2018

Conor Hale / FiercePharma

Pfizer has tapped Antares Pharma for the development of a self-administered combination drug-device rescue pen for an undisclosed medicine, shortly after investing $465 million in a new sterile injectables plant.

Pfizer will pay for the product’s development and lead the push for FDA approval, while Antares will provide its QuickShot auto-injector.

Under a separate supply deal, Antares will deliver the finished, fully packaged product to Pfizer at cost, plus margin, while the Big Pharma will then be responsible for its commercialization. While full financial details are not available, Antares will receive royalties on net sales.

“We look forward to working closely with Pfizer throughout the development phase of this combination product and assisting them with the FDA drug device approval process,” Antares President and CEO Robert Apple said in a statement (PDF). The Ewing, New Jersey-based company’s stock was up more than 8% in premarket trading.

Pfizer’s massive, 400,000-square-foot addition planned for its Portage, Michigan, manufacturing plant is expected to add 450 new jobs when its fully operational in 2024.

The site is already one of the company’s primary facilities for sterile injectable, liquid and semisolid medicines—as well as for active pharmaceutical ingredients—and currently manufactures more than 150 products.

Pfizer previously contracted with Antares in a similar delivery device deal through its consumer health arm in 2011, with its targets and financial details undisclosed as well.

“This development agreement between Antares and Pfizer further expands our portfolio of pipeline-partnered products,” including the number of products using the company’s QuickShot auto-injector platform, Apple said.

Antares also maintains collaborations with Actavis, Meda, AMAG Pharmaceuticals and Teva. Antares’ other proprietary products include Otrexup (methotrexate) subcutaneous injection and the investigational testosterone replacement therapy Xyosted, currently under FDA review with decision expected by the end of September.


Previous publication Next publication

Media Center

  • 31 October 2018

    Scientists unveiled a more effective approach for assessing drug response

    Scientists from Eli Lilly and Company, the Icahn School of Medicine at Mount Sinai (New York, USA) and Sema4 (Stamford, USA) released results from a proof-of-concept study demonstrating that patient-derived cells offer a more effective approach for assessing drug response than conventional methods.

  • 30 October 2018

    Researchers developed an AI approach to identify antibiotic resistance genes

    Researchers at the University of California San Diego (USA) have developed an approach that uses machine learning to identify and predict which genes make infectious bacteria resistant to antibiotics. The approach was tested on strains of Mycobacterium tuberculosis – the bacteria that cause tuberculosis (TB) in humans. It identified 33 known and 24 new antibiotic resistance genes in these bacteria.

  • 29 October 2018

    Expanding the reach of gene editing with a new CRISPR enzyme

    The CRISPR-Cas9 gene editing system has been widely studied because of its potential therapeutic applications, but limitations in the number of locations on the genome it can target remain a major drawback. Now scientists at the Massachusetts Institute of Technology have identified a new Cas9 enzyme that they say can help CRISPR reach more gene mutations.

  • 26 October 2018

    Biotech Backed by Bain, Pfizer loads prime CNS assets into new biotech

    Pfizer has followed through on its pledge to divest a hunk of its neuroscience R&D, spinning several programs into a new company called Cerevel Therapeutics backed by $350 million in venture funding. Pfizer is contributing a trio of clinical-stage drug candidates—including a Parkinson’s therapy due to start phase 3 testing next year—plus a clutch of earlier-stage programs, while Bain Capital and affiliates stumped up the initial funding.

Read more